Small, 3D-printed devices, designed to be implanted directly under the skin, could allow people with type 1 diabetes to ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Forty-one percent of patients in the insulin pen group used insulin pens after discharge, while only 10% of patients in the vial and syringe group switched to insulin pens after discharge (p = 0.016).

Patients receiving insulin with a vial and syringe who converted to pen therapy were compared with those who continued to use the vial and syringe method in both unmatched comparisons (n = 560 and ...

The global Insulin Delivery Device Market, valued at US$32.6 billion in 2024 stood at US$35.3 billion in 2025 and is ...

Wegovy is being made available in five dosing strengths with an easy-to-use pen device, which does away the use of syringes ...

While many systems already pair continuous glucose monitors (CGMs) and insulin pumps, PharmaSens and SiBionics may have ...

The Diabetes Devices Market was valued at US$ 33.4 Billion in 2024 and is projected to reach US$ 64.8 Billion by 2033, growing at a CAGR of 7.7%. The U.S. diabetes devices market is witnessing strong ...

Insulin pens are not as intimidating as a medical syringe, and some say they hurt less than syringes. The pen is already prefilled, so drawing insulin into a needle is unnecessary.

The global Insulin Delivery Device Market, valued at US$32.6 billion in 2024 stood at US$35.3 billion in 2025 and is projected to advance at ...

After a decade of being the primary supplier of human insulin pens in South Africa, Novo decided against bidding for the 2024 tender. Instead, it decided to phase out the easy-to-use pens and tendered ...